Tampere University, Faculty of Medicine and Health Technology’s Post

Hypertrophic cardiomyopathy (HCM) is a cardiac disease in which several gene mutations affect its manifestation. HCM thickens heart walls and increases the risk of irregular heartbeats and sudden death. Affecting up to five in 1,000 people, it's the most common inherited cardiac disease and a leading cause of sudden death in young individuals. Despite the complexity of the disease, current approaches treat HCM as a single disease, resulting in less effective care. Enter SMASH-HCM, a €10 million EU project led by Tampere University, poised to revolutionize HCM management! SMASH-HCM develops a sophisticated digital twin – a digital replica of the heart and blood vessels, complemented by sympathetic nerve control and integrated with AI and clinical data. This advanced digital tool enhances risk assessment and enables tailored treatments for individual patients. Doctors gain improved diagnostics and can provide precise lifestyle advice. Moreover, the new tool supports healthcare, technology, and pharmaceutical industries by facilitating target discovery and cardiac safety testing. Ultimately, it promises superior treatments, outcomes, and global healthcare cost savings. 📸 Jonne Renvall / Tampere Uni #HCMawareness #DigitalHealth #PersonalizedMedicine #CardiologyInnovation #PatientCare #MedicalResearch #HealthTech #SMASHHCM

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics